Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04937699 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotableChangedSponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University to Second Affiliated Hospital, Zhejiang University, School of Medicine
NotablePrimary and study completion dates: Dec 31, 2025 to Dec 31, 2026v6
NotableTrial status: Not Yet Recruiting to Recruitingv5Show 5 more changesShow less
Primary completion date: Jun 2024 to Dec 31, 2025
Study completion date: Jun 2025 to Dec 31, 2025
Start date changed from estimate of Jan 2023 to Mar 28, 2023
Eligibility criteria revised
Site details revised
MinorEligibility criteria shortened, about 22 words
Study description shortened, about 3 words
v4
NotableStart date: Dec 2021 to Jan 2023v3Show 10 more changesShow less
Enrollment target: 2856 to 2690
Primary completion date: Dec 2023 to Jun 2024
Study completion date: Dec 2023 to Jun 2025
Interventions: Low-Does Ticagrelor monotherapy (Drug), Standard-Does Ticagrelor plus aspirin (Drug) to Sequential monotherapy of Ticagrelor and clopidogrel (Drug), Standard-DAPT of Ticagrelor plus aspirin (Drug)
Eligibility criteria shortened, about 7 words
Secondary endpoints: details revised at 1 of 1 entry
Study description shortened, about 61 words
Site details revised
Publications: 10 to 12
Study title expanded, about 1 word
NotableEnrollment target: 510 to 2856v2Show 5 more changesShow less
Primary endpoint revised
Secondary endpoints: details revised at 1 of 1 entry
Site contact updated
Eligibility criteria shortened, about 2 words
Study description expanded, about 3 words
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The MATE study is a randomized, multicenter, open-label, investigator-initiated clinical trial aimed to evaluate efficacy and safety of sequential monotherapy of ticagrelor and clopidogrel in patients with acute coronary syndrome (ACS) after coronary intervention. Standard DAPT of aspirin plus ticagrelor will be given for the first 1 month after PCI. After 1 month, event-free subjects will be randomized at 1:1 ratio into receiving standard DAPT (DAPT) until 12months , or switch to ticagrelor monotherapy for another 5 months , and further de-escalated to monotherapy of clopidogrel for the last 6 months(SAPT).